Informed Consent
The process by which a clinical trial participant is fully informed about the study and voluntarily agrees to participate. Participants must be told about the purpose, procedures, risks, benefits, alternatives, and their right to withdraw at any time without consequence.
Technical Context
Consent documents must include: study purpose, procedures, duration, experimental aspects, risks and discomforts, potential benefits, alternatives to participation, confidentiality protections, compensation for injury, contacts for questions, and statement of voluntary participation with right to withdraw. Consent must be obtained before any study procedures and re-obtained if the protocol changes materially. Special considerations: children require assent (age-appropriate consent) plus parental permission; patients with cognitive impairment may require legally authorised representative consent; emergency research has specific waiver provisions. For peptide drug trials, consent must specifically address injection-related risks, immunogenicity potential, and any class-specific safety concerns (e.g. thyroid C-cell tumour risk for GLP-1 RAs).